Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Heron Therapeutics Inc HRTX

Healthcare Biotechnology
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and... see more

Recent & Breaking News (NDAQ:HRTX)

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Corporate Progress

PR Newswire November 7, 2018

Heron Announces FDA Submission of HTX-011 NDA for Postoperative Pain Management

PR Newswire October 31, 2018

Factors of Influence in 2018, Key Indicators and Opportunity within Cloud Peak Energy, Ralph Lauren, CytomX Therapeutics, Extreme Networks, Heron Therapeutics, and Alteryx — New Research Emphasizes Economic Growth

GlobeNewswire October 12, 2018

Heron Therapeutics to Present at the 2018 Cantor Global Healthcare Conference

PR Newswire September 24, 2018

New Research Coverage Highlights East West, Heron Therapeutics, Invacare, CNO Financial Group, Fortinet, and Realogy — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire August 13, 2018

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress

PR Newswire August 8, 2018

Heron Therapeutics Announces Pricing of Public Offering of Common Stock

Business Wire June 25, 2018

Heron Therapeutics Announces Public Offering of Common Stock

Business Wire June 25, 2018

HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDA

Business Wire June 21, 2018

Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation

Business Wire June 21, 2018

Heron Therapeutics to Present at the Jefferies 2018 Healthcare Conference

Business Wire May 29, 2018

Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

Benzinga.com  May 19, 2018

Analysis: Positioning to Benefit within Advaxis, e.l.f. Beauty, Heron Therapeutics, PVH, Energy Recovery, and A. O. Smith — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire May 14, 2018

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress

Business Wire May 10, 2018

Heron Therapeutics to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference

Business Wire May 9, 2018

10 Stocks To Watch For March 29, 2018

Benzinga.com  March 29, 2018

Heron Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

Business Wire March 28, 2018

Heron Therapeutics Announces Proposed Public Offering of Common Stock

Business Wire March 28, 2018

Heron Therapeutics to Present at the 17th Annual Needham Healthcare Conference

Business Wire March 21, 2018

Mid-Afternoon Market Update: NASDAQ Slides Over 2.5%; Micro Focus Shares Plummet

Benzinga.com  March 19, 2018